An expanded label for Amarin's fish-oil drug looks more likely, but - STAT
An expanded label for Amarin's fish-oil drug looks more likely, but STATThe company says the FDA is “unlikely” to convene an advisory committee meeting to review data on an expanded use of its heart drug Vascepa.